Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations.

Autor:	Moyer GC; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Bannow BS; The Hemophilia Center, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Thornburg C; Rady Children's Hospital, University of San Diego, San Diego, CA, USA.; Rady Children's Hospital San Diego, San Diego, CA, USA., Rosovsky R; Massachusetts General Hospital, Boston, MA, USA., Wang TF; The Ohio State University James Cancer Hospital, Columbus, OH, USA., Woller S; Intermountain Medical Center, Murray, UT, USA.; University of Utah School of Medicine, Salt Lake City, UT, USA., Thornhill D; Hemophilia & Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Kreuziger LB; BloodCenter of Wisconsin, Milwaukee, WI, USA.; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Jazyk:	angličtina
Zdroj:	Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2018 Dec; Vol. 24 (9_suppl), pp. 209S-216S. Date of Electronic Publication: 2018 Oct 02.
DOI:	10.1177/1076029618804080
Abstrakt:	Venous thromboembolism (VTE) is a highly morbid condition with several available oral anticoagulant treatment options. Numerous studies have been published comparing warfarin to direct oral anticoagulants; however, several populations remain underrepresented in these reports. We surveyed members of The Venous ThromboEmbolism Network U.S. working group regarding their oral anticoagulant preferences for the treatment of VTE in different and challenging populations. In individuals with VTE and no other medical comorbidities, respondents preferred either rivaroxaban (48.7%) or apixaban (48.7%). Apixaban (53.3%) was preferred in elderly individuals with an increased risk of bleeding. Warfarin was preferred in individuals with liver or kidney dysfunction (42% and 47%), altered metabolism (>55%), and antiphospholipid antibody syndrome (84.2%). Low-molecular-weight heparin was preferred in individuals with malignancy (56.6%), followed by edoxaban (23.7%). These findings may help guide clinicians when choosing an anticoagulant in these challenging situations and demonstrate the urgent need for additional study in these groups.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu